Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Michael K. McCracken et al.|Nature Medicine|2020Cited by 88
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Michael Koren et al.|The Journal of Infectious Diseases|2020Cited by 24
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trialKirsten E. Lyke, Robert Edelman, Joel V. Chua et al.|The Lancet Infectious Diseases|2024Cited by 24
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, Leyi Lin et al.|The Lancet Infectious Diseases|2023Cited by 23
Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Humans is Diminished by Priming with a Yellow Fever or Japanese Encephalitis Virus Vaccine: Elucidating Immunologic Interference between Flavivirus VaccinesKayvon Modjarrad, Nelson L. Michael, Mihret F. Amare et al.|The Journal of Immunology|2020Cited by 1